TY - JOUR
T1 - Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates
T2 - A review of the current status
AU - Moatshe, Gilbert
AU - Morris, Elizabeth R.
AU - Cinque, Mark E.
AU - Pascual-Garrido, Cecilia
AU - Chahla, Jorge
AU - Engebretsen, Lars
AU - Laprade, Robert F.
N1 - Funding Information:
LE: Arthrex Inc (IP royalties, paid consultant), Biomet (research support), iBalance (stock or stock options), Smith & Nephew (research support). RFL: Arthrex Inc (consultant, IP royalties, research support), Ossur (consultant, research support), Smith & Nephew (consultant, IP royalties, research support). GM: research support from South Eastern Norway Health Authorities (Helse Sør-Øst) and Arthrex Inc.
Publisher Copyright:
© 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - ABSTRACT — Knee pathologies including focal cartilage injuries, osteoarthritis (OA), and ligament injuries are common. The poor regeneration and healing potential of cartilage has led to the search for other treatment modalities with improved healing capacity. Furthermore, with an increasing elderly population that desires to remain active, the burden of knee pathologies is expected to increase. Increased sports participation and the desire to return to activities faster is also demanding more effective and minimally invasive treatment options. Thus, the use of biologic agents in the treatment of knee pathologies has emerged as a potential option. Despite the increasing use of biologic agents for knee pathology, there are conflicting results on the efficacy of these products. Furthermore, strong data supporting the optimal preparation methods and composition for widely used biologic agents, such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), largely remain absent from the literature. This review presents the literature on the most commonly employed biologic agents for the different knee pathologies.
AB - ABSTRACT — Knee pathologies including focal cartilage injuries, osteoarthritis (OA), and ligament injuries are common. The poor regeneration and healing potential of cartilage has led to the search for other treatment modalities with improved healing capacity. Furthermore, with an increasing elderly population that desires to remain active, the burden of knee pathologies is expected to increase. Increased sports participation and the desire to return to activities faster is also demanding more effective and minimally invasive treatment options. Thus, the use of biologic agents in the treatment of knee pathologies has emerged as a potential option. Despite the increasing use of biologic agents for knee pathology, there are conflicting results on the efficacy of these products. Furthermore, strong data supporting the optimal preparation methods and composition for widely used biologic agents, such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), largely remain absent from the literature. This review presents the literature on the most commonly employed biologic agents for the different knee pathologies.
UR - http://www.scopus.com/inward/record.url?scp=85028560947&partnerID=8YFLogxK
U2 - 10.1080/17453674.2017.1368899
DO - 10.1080/17453674.2017.1368899
M3 - Article
C2 - 28831830
AN - SCOPUS:85028560947
SN - 1745-3674
VL - 88
SP - 670
EP - 674
JO - Acta Orthopaedica
JF - Acta Orthopaedica
IS - 6
ER -